
Overview
Status
Active
Registry date
2009-07-10
Share capital
5,000.00 PLN
Activity description
Meamedica operates specialist medical offices staffed by five specialist doctors. The team consists of experienced clinicians, most of whom also teach at the Medical University of Gdansk; its services include endocrinology.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $4,056 |
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 226 days for 2024).
- 202520/08/2026
- 202426/02/2026
- 202317/02/2025
- 202223/04/2023
- 202104/05/2022
- 202004/05/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 334.16kMedianUSD 443.52kAverageUSD 1.75m
Net profit
This companyUSD 26.23kMedianUSD 14.31kAverageUSD 129.52k
Operating costs
This companyUSD 303.35kMedianUSD 397.10kAverageUSD 1.56m
Assets
This companyUSD 208.08kMedianUSD 173.92kAverageUSD 1.02m
Industry
Offer
- Endocrinology
- Gastroenterology
- Nephrology
- Pulmonology
- Rheumatology
- Dermatology
- Varicose vein sclerotherapy
- Diagnostic tests
Website technology
- Website
- WordPress
- Elementor
- Contact and booking
- Z ZnanyLekarz
Authorized Representatives
Sławomir Kazimierz Lizakowski – President of the Management Board
Manner of representation
Each member of the management board is authorized independently to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Sławomir Lizakowskiage 57 | 50 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 22, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezydent Miasta Gdańsk |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Puls-Medicsp. z o.o. | $967,172.72 | pulsmedic.pl | ||
| Mediss Medicalsp. z o.o. | $949,354.62 | medissmedical.pl | ||
| Dermedicasp. z o.o. | $938,432.07 | dermedica.info | ||
| Niepubliczny Zakład Opieki Zdrowotnej Wolne Miastosp. z o.o. | $930,369.15 | przychodniawolnemiasto.pl | ||
| Medicorumsp. z o.o. | $533,790.52 | medicorum.pl | ||
| Magmedsp. z o.o. | $452,490.95 | magmed.com.pl | ||
| Professmedsp. z o.o. | $406,049.54 | professmed.pl | ||
| Maximed Specjalistyczne Gabinety Lekarskiesp. z o.o. | $359,842.30 | maximed.com.pl | ||
| Smartheartsp. z o.o. | $133,168.34 | smartheart.pl | ||
| Endoktorzysp. z o.o. | $117,479.03 | endoktorzy.pl |
Change history
| Date | Event | |
|---|---|---|
| 2021-06-23 | PKD change (Removed: 8 codes; Added: 1 code) | |
| 2013-08-27 | Address change (Dębinki 7 D, 80-211, Gdańsk → Grunwaldzka 74/1, 80-244, Gdańsk) | |
| 2012-06-28 | Address change (Bł. Królowej Jadwigi 8, 81-586, Gdynia → Dębinki 7 D, 80-211, Gdańsk) | |
| 2012-06-28 | Name change (Skancel → Meamedica) | |
| 2012-06-28 | PKD change (Removed: 16 codes; Added: 13 codes) |
FAQ
The main business activity of Meamedica focuses on specialist medical practice activities.
The company was registered in the Polish National Court Register (KRS) on July 10, 2009.
The headquarters is located at: Grunwaldzka 74, 80-244 Gdańsk.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD 334,161 in 2025, which is an increase of 12.9% compared to 2024.
Yes, the company recorded a net profit of USD 26,228 in 2025.
The largest operating cost category falls under employee remuneration. This category amounted to USD 37,269 in 2025, representing 12% of all operating expenses.
Last updated: 2026-10-07